Related Experiment Videos
Intrauterine baclofen exposure: a multidisciplinary approach
Lisa R Moran1, Pamela G Almeida, Susan Worden
1Department of Pharmacy-GB005, Massachusetts General Hospital, 55 Fruit St, Boston, Massachusetts 02114, USA. lrmoran@partners.org
Pediatrics
|August 3, 2004
Summary
Maternal baclofen use during pregnancy is rare, posing risks for newborns. A multidisciplinary team approach successfully managed a case, minimizing neonatal withdrawal and ensuring a positive outcome for mother and infant.
Area of Science:
- Perinatology
- Neonatal Pharmacology
- Maternal-Fetal Medicine
Background:
- Maternal baclofen use in pregnancy presents unique challenges due to limited data on neonatal risks.
- Antispasmodic medications during gestation require careful consideration for potential adverse effects on the neonate.
- Uncertainty exists regarding the safe management of infants exposed to baclofen in utero.
Observation:
- A case of maternal oral baclofen use during pregnancy was managed using a specialized peripartum plan.
- The management strategy integrated expertise from neonatology, nursing, pharmacy, neurology, and lactation services.
- Parental input was a key component of the collaborative, consensus-based approach.
Findings:
- The implemented team-based management plan successfully minimized the risk of neonatal withdrawal syndrome.
- Close monitoring and a structured approach facilitated a safe outcome for the infant.
- The collaborative strategy proved effective in managing this uncommon drug exposure scenario.
Implications:
- This case demonstrates the feasibility and success of a multidisciplinary approach for managing rare maternal medication exposures.
- Such consensus-driven protocols can enhance the safety of infants exposed to medications like baclofen during pregnancy.
- Effective peripartum management strategies are crucial for mitigating neonatal risks associated with unusual maternal drug use.